58 results about "Phosphatidyl Glycerol" patented technology

The invention relates to an oral drug delivery system which delivers biologically active substances to the mucosal tissue of the intestine utilizing novel polymerized liposomes. Novel polymerizable fatty acids having a polymerizable group, a surfactant group, and a functional group, and optionally coupled to ligands which target mucosal tissue in the intestine are disclosed. Novel negatively charged polymerizable lipids which have phosphatidyl inositol (PI), phosphatidyl glycerol (PG) or phosphatidyl serine (PS) groups on a polymerizable backbone are also described.

The invention discloses an oxaliplatin liposome, a preparation method and application thereof. The oxaliplatin liposome contains oxaliplatin, phospholipid and cholesterol, wherein, based on the total weight of the phospholipid, the phospholipid comprises the following components in percentage by weight: 75 to 90 percent of phosphatidylcholine (PC), and 10 to 25 percent of phosphatidyl glycerol (PG) and phosphatidic acid (PA); the weight ratio of the oxaliplatin to the phospholipid is 1:3-20, and the weight ratio of the cholesterol to the phospholipid is 1:2-10.

The invention discloses a method for detecting bis-phospholipid in a high flux manner. The method comprises the following steps: separately derivatizating a bis-phospholipid standard product and a phosphatidyl glycerol standard product, separating and detecting the bis-phospholipid and phosphatidyl glycerol standard product by using liquid chromatography tandem mass spectrometry, and establishinga high-flux liquid chromatography tandem mass spectrometry database related to the bis-phospholipid; derivatizating a sample, separating and detecting the sample by using the liquid chromatography tandem mass spectrometry, so as to obtain bis-phospholipid characteristic ions of the sample; and searching the obtained bis-phospholipid characteristic ions in the high-flux liquid chromatography tandemmass spectrometry database, and acquiring the information related to the bis-phospholipid in the sample. According to the method, by establishing the high-resolution database, the high-flux analysisfor BMP can be realized; and by adopting the derivatization method, not only can the signal intensity of the BMP be improved, but also the interference of isomeride can be reduced, and the accuracy ofa data analysis result and the repetition of the data analysis result can be improved.

This invention provides methods and compositions for localized delivery of IL-12 to a desired site. The composition comprises liposomes carrying IL-12. The liposomes comprise phosphatidyl choline, phosphatidyl glycerol and cholesterol. The size and composition of the liposomes is such that there is minimal leakage into the systemic circulation. These compositions can be used for delivery of IL-12 to selected sites such as tumors.

The invention discloses a fungal fluorescent staining fluid, which is prepared from, by weight (%), 0.08-0.012% of 5-carboxy flouorescein, 0.045-0.055% of fungal primer ITS4, 8-13% of potassium hydroxide, 28-33% of glycerinum, 0.45-0.55% of diphosphatidyl glycerol, 0.07-0.13% of ascorbic acid, 53.363-63.427% of water. Through adding 5-carboxy flouorescein and fungal primer, the fungal primer ITS4forms a stem ring structure under a free state, thus the fluorescent recession can be effectively avoided; 5-carboxy flouorescein in the of potassium hydroxide solution can penetrate through a fungalcell wall and a cell film to generate specificity combination with alkali group of the ribonucleic acid gene interval zone of fungal ribosome; at the moment, the stem ring structure is opened and shows fluorescence through microscopic examination under a fluorescence microscope; potassium hydroxide can smelt fungal cuticle in the dyeing process, thus the fungal primer ITS 4 can rapidly enter the internal action of the fungal cell; besides, for the fluorescent recession inhibitor is added in the formula, the fluorescence primer can be kept for a long term after the specificity combination withthe alkali group of the ribonucleic acid gene interval zone of fungal ribosome.

The invention provides cefepime hydrochloride proliposome which comprises the following components by weight part: 3-20 parts of cefepime hydrochloride, 5-40 parts of dipalmitoyl phosphatidyl glycerol, 1-30 parts of cholesterol and 3-50 parts of proppant which consists of sodium chloride and mannitol with a weight ratio of 1:4. The cefepime hydrochloride proliposome greatly improves the stability, has in-vivo degradation of drug carrier liposome, no toxicity and no immunogenicity and can improve the medical therapeutic index and reduce drug toxicity and side effects. The cefepime hydrochloride proliposome can be prepared by conventional processing equipment and industrially and efficiently produced and has low production cost.

The invention discloses an olmesartan ester liposome solid preparation and a preparation method thereof. Active ingredient-olmesartan ester, particularly-combined phosphatidyl inositol, di-stearoyl phosphatidyl glycerol, cholesterol succinate and tween 80 are prepared into liposome, the stability, the dissolution rate and the bioavailability of the preparation is greatly increased, the action is stable and lasting, and the curative effect is significant. The product quality of the preparation is increased, and the toxic and side effects are reduced.

The invention discloses ginkgolide B lipid microsphere injection and a preparation method thereof. The lipid microsphere injection is prepared by ginkgolide B, DOPE (dioleoyl phosphatidyl ethanolamine), polyoxyl (40) hydrogenated castor oil, distearoyl phosphatidyl glycerol and PEG (polyethylene glycol) 400 in a specific weight ratio. The lipid microsphere injection has the advantages of even microsphere particle sizes, good stability and entrapment efficiency, and very low leakage rate; the problems that the ginkgolide B is easy to overoxidize and is prone to hydrolysis failure in vivo are solved; and the preparation method is good in reproducibility and suitable for industrialized production.

The invention discloses a capsaicin liquid crystal nano spray preparation for promoting skin wound healing and a preparation method thereof. The capsaicin liquid crystal nano spray preparation is prepared from, by weight, 0.1-0.5% of capsaicin, 50-70% of a liquid crystal material, 5-10% of chitosan, 5-10% of a surfactant, 10-15% of a cosolvent and the balance water. The liquid crystal material isformed by mixing phosphatidyl glycerol and glyceryl dioleate in the weight ratio of 1:(1-3). The preparation method of the spray preparation comprises the steps that the capsaicin, the liquid crystalmaterial and the chitosan are dissolved and dispersed to form drug-loaded liquid crystal nanoparticles under the action of the cosolvent, the stability of the drug-loaded liquid crystal nanoparticlescan be greatly improved through the above operation, and the slow-release effect is obvious. The chitosan is combined with cysteine in the body to form a film on an affected part, the chitosan also has an antibacterial effect, the effects of isolating and protecting the affected part are achieved, and the action time of the medicine is prolonged, so that the local medicine concentration is obviously increased, the medicine takes effect easily, and wound healing is promoted.

The invention relates to a sarpogrelate hydrochloride lipidosome solid preparation and a preparation method thereof. The preparation method comprises the following steps: selecting sarpogrelate hydrochloride, dilauroyl phosphatidylcholine, phosphatidyl ethanolamine, phosphatidyl glycerol and cholesterol with specific weight ratio to prepare sarpogrelate hydrochloride lipidosome with excellent quality; and preparing the solid preparation by the common preparation method. Compared with the conventional preparation, the preparation provided by the invention improves the stability, the bioavailability and the product quality of the preparation and reduces the toxic or side effect.

The invention discloses a preparation method of a cinnamaldehyde essential oil liposome antibacterial double-layer membrane with regulated releasing. The method comprises the steps that (1), cinnamaldehyde heat-sensitive essential oil liposome is prepared taking dipalmitoyl phosphatidyl glycerol, distearoyl phosphatidylcholine, cholesterol and cinnamaldehyde essential oil as raw materials; (2),thecinnamaldehyde heat-sensitive essential oil liposome and casein are taken as raw materials to prepare heat-sensitive protein composite liposome; (3), a pectin cast membrane is prepared; (4), zein powder is taken to be dissolved in an ethanol aqueous solution to obtain a basic spinning solution, the heat-sensitive protein composite liposome is added to the basic spinning solution to obtain a static spinning solution, the pectin cast membrane is taken as a recipient, and static spinning is conducted to obtain the cinnamaldehyde essential oil liposome antibacterial double-layer membrane. By means of the method, the stability of essence oil and the mechanical performance of the membrane can be improved, and the prevention of the generation of putrefying bacteria in the environment with relatively higher temperature and sustained releasing can be achieved.

The invention discloses a fluoxetine hydrochloride liposome solid preparation and a preparation method of the fluoxetine hydrochloride liposome solid preparation. Active ingredients fluoxetine hydrochloride and egg yolk phosphatidyl glycerol, dimyristoyl phosphatidyl choline, cholesterol succinate and span 40 in specific combination are prepared into lipidosome, the stability, the dissolvability and the bioavailability of medicine are greatly improved, in addition, the effect is stable and durable, and the curative effect is obvious. The preparation disclosed by the invention has the advantages that the product quality of the preparation is improved, and the toxic or side effect is reduced.

The invention provides a repaglinide liposome solid preparation, and a preparation method thereof. According to the invention, repaglinide, ovolecithin, soyasterol, and dilauroyl phosphatidyl glycerol with a certain weight ratio are prepared into repaglinide liposome with excellent quality; and the repaglinide liposome is prepared into a solid preparation with a common preparation method. Compared with existing preparations, the preparation provided by the invention is advantaged in substantially improved preparation stability, bioavailability, product quality, and release-retarding effect, and reduced toxic and side effects.